{{expand English|Bupropion|fa=yes}}
{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443491992
| IUPAC_name = (±)-2-(''tert''-Butylamino)-1-(3-chlorophenyl)propan-1-one
| image = Bupropion 1.svg
| alt = Skeletal formula of bupropion
| image2 = (S)-bupropion ball-and-stick xtal 2009.png
| width2 = 260
| alt2 = Ball-and-stick model of the (S) isomer of the bupropion molecule
| imagename = 1 : 1 mixture (racemate)
| drug_name = 安非他酮

<!--Clinical data-->
| pronounce ={{IPAc-en|b|juː|ˈ|p|r|oʊ|p|i|.|ɒ|n}} {{respell|bew|PROH|pee-on}}
| tradename = Wellbutrin, Elontril, Zyban
| Drugs.com = {{drugs.com|monograph|bupropion-hydrochloride}}
| MedlinePlus = a695033
| licence_US = Bupropion
| pregnancy_AU = B2
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| dependency_liability: 几乎没有
| addiction_liability = 几乎没有
| routes_of_administration = 医疗用途: [[口服|口服]]<br />娱乐: [[鼻腔内|鼻腔内]], [[静脉注射|静脉注射]]

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 84% (安非他酮), 77% (羟安非他酮代谢产物), 42% (苏氨酸氢化安非他酮代谢物)<ref name = EMC>{{cite web|title=Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)|work=electronic Medicines Compendium|publisher=GlaxoSmithKline UK|date=1 August 2013|accessdate=22 October 2013|url=http://www.medicines.org.uk/emc/medicine/2948/SPC/Zyban+150+mg+prolonged+release+film-coated+tablets/|archive-date=2015-09-20|archive-url=https://web.archive.org/web/20150920011307/http://www.medicines.org.uk/emc/medicine/2948/SPC/Zyban+150+mg+prolonged+release+film-coated+tablets/|dead-url=no}}</ref>
| metabolism = [[肝脏|肝脏]] (大部分是[[CYP2B6|CYP2B6]]-介导的羟化, 但有时候也是[[CYP1A2|CYP1A2]], [[CYP2A6|CYP2A6]], [[CYP2C9|CYP2C9]], [[CYP3A4|CYP3A4]], [[CYP2E1|CYP2E1]]和[[CYP2C19|CYP2C19]])<ref name = EMC/><ref name = PREXATON/><ref name = DM/><ref>{{cite journal|last1=Zhu|first1=A. Z. X.|last2=Zhou|first2=Q.|last3=Cox|first3=L. S.|last4=Ahluwalia|first4=J. S.|last5=Benowitz|first5=N. L.|last6=Tyndale|first6=R. F.|title=Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes|journal=Drug Metabolism and Disposition|date=3 September 2014|volume=42|issue=11|pages=1971–1977|doi=10.1124/dmd.114.060285|pmid=25187485}}</ref>
| elimination_half-life = 11小时(短期给药;母体化合物)<ref>{{cite book | name-list-format = vanc  | isbn = 978-0-07-162442-8 | title = [[Goodman_and_Gilman's_The_Pharmacological_Basis_of_Therapeutics|Goodman and Gilman's The Pharmacological Basis of Therapeutics]] | edition = 12th | author = Brunton, L; Chabner, B; Knollman, B | year = 2010 | publisher = McGraw-Hill Professional | location = New York }}</ref> 14–21小时(长期给药; 母体化合物 - 取决于形式),<ref name = EMC/><ref name = DM/><ref name = ZYBAN/> 20小时(羟安非他酮), 33小时(赤藓糖氢化安非他酮), 37小时(苏氨酸氢化安非他酮)<ref name = EMC/><ref name = DM/><ref name = ZYBAN/><ref name = Wellbutrin>{{cite web|title=WELLBUTRIN (bupropion hydrochloride) tablet, film coated [GlaxoSmithKline LLC]|work=DailyMed|publisher=GlaxoSmithKline LLC|date=March 2013|accessdate=22 October 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60525754-0d2b-4ba4-918a-1c9d3eff89b2|archive-date=2013-10-23|archive-url=https://web.archive.org/web/20131023061300/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60525754-0d2b-4ba4-918a-1c9d3eff89b2|dead-url=no}}</ref>
| excretion = [[肾脏|肾脏]] (87%; 0.5% 原型), [[粪便|粪便]] (10%)<ref name = PREXATON>{{cite web|title=Prexaton Bupropion hydrochloride PRODUCT INFORMATION|work=TGA eBusiness Services|publisher=Ascent Pharma Pty Ltd|date=2 October 2012|accessdate=22 October 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-03529-3|archive-date=2016-12-07|archive-url=https://web.archive.org/web/20161207174330/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-03529-3|dead-url=no}}</ref><ref name = DM>{{cite web|title=BUPROPION HYDROCHLORIDE tablet, film coated [Sandoz Inc]|work=DailyMed|publisher=Sandoz, Inc.|date=April 2013|accessdate=22 October 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce024abb-c5d5-45c8-bc3c-afe18b1bebe9|archive-date=2013-07-04|archive-url=https://web.archive.org/web/20130704035041/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce024abb-c5d5-45c8-bc3c-afe18b1bebe9|dead-url=no}}</ref><ref name = ZYBAN>{{cite web|title=PRODUCT INFORMATION ZYBAN® SUSTAINED RELEASE TABLETS|work=TGA eBusiness Services|publisher=Aspen Pharmacare Australia Pty Ltd|date=19 April 2013|accessdate=22 October 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01138-1|archive-date=2016-12-07|archive-url=https://web.archive.org/web/20161207175501/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01138-1|dead-url=no}}</ref>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 34841-39-9
| ATC_prefix = N06
| ATC_suffix = AX12
| PubChem = 444
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01156
| IUPHAR_ligand = 7135
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 431
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 01ZG3TPX31
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07591
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3219
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 894
| synonyms = 3-Chloro-''N''-''tert''-butyl-β-keto-α-methylphenethylamine;<br />3-Chloro-''N''-''tert''-butylcathinone

<!--Chemical data-->
| C=13 | H=18 | Cl=1 | N=1 | O=1
| molecular_weight = 239.74 g/mol
| smiles = O=C(C(C)NC(C)(C)C)C1=CC=CC(Cl)=C1
| InChI = 1/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SNPPWIUOZRMYNY-UHFFFAOYSA-N
}}
'''安非他酮'''（[[國際非專利藥品名稱|國際非專利藥品名稱]]：{{lang|en|Bupropion}}，舊名：amfebutamone） 或 '''盐酸安非他酮'''，商品名'''威博雋'''（Wellbutrin），是一种主要作为[[抗抑郁药|抗抑郁药]]和[[戒烟药|戒烟药]]使用的[[药物|药物]]、也可用作治療[[注意力不足過動症|注意力不足過動症]]的第二線藥品（second-line medication）與[[中樞神經刺激劑|中樞神經刺激劑]]合併使用，或作為中樞神經刺激劑的替代方案。<ref name="MortonMorton1999">{{cite book|name-list-format=vanc|author1=Dr. Ian Morton|author2=I.K. Morton|author3=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=http://books.google.com/books?id=mqaOMOtk61IC&pg=PA57|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=57–|access-date=2015-09-02|archive-date=2016-04-27|archive-url=https://web.archive.org/web/20160427122003/https://books.google.com/books?id=mqaOMOtk61IC&pg=PA57|dead-url=no}}</ref><ref>{{cite book|name-list-format=vanc|title=Dictionary of Organic Compounds|url=http://books.google.com/books?id=w5dpoQRjGNEC&pg=PA104|publisher=CRC Press|isbn=978-0-412-54090-5|pages=104–|access-date=2015-09-02|archive-date=2016-04-30|archive-url=https://web.archive.org/web/20160430152849/https://books.google.com/books?id=w5dpoQRjGNEC&pg=PA104|dead-url=no}}</ref><ref>{{cite book|name-list-format=vanc|title=Index Nominum 2000: International Drug Directory|url=http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA38|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=38–|access-date=2015-09-02|archive-date=2016-04-30|archive-url=https://web.archive.org/web/20160430130645/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA38|dead-url=no}}</ref> <ref name=CNS09>{{cite journal |author=Wigal SB |title=Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults |journal=CNS Drugs|volume=23 Suppl 1 |pages=21–31 |year=2009 |pmid=19621975 |doi=10.2165/00023210-200923000-00004 |url=}}</ref><ref>{{Cite journal|last=Childress|first=A. C.|last2=Sallee|first2=F. R.|date=2012|title=Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder|journal=Drugs of Today (Barcelona, Spain: 1998)|volume=48|issue=3|pages=207–217|doi=10.1358/dot.2012.48.3.1750904|issn=1699-3993|pmid=22462040}}</ref> 安非他酮在美国是最常用的抗抑郁药之一，在其他许多英语国家亦是如此。<ref name = PMH/><ref name = MD>{{cite web|title=Bupropion|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|location=London, UK|date=22 October 2013|accessdate=18 July 2014|url=https://www.medicinescomplete.com/mc/martindale/current/ms-21667-v.htm|editor=Brayfield, A}}</ref> 以商品名'''载班'''（Zyban）出售的安非他酮缓释片用作戒烟药使用，并且使用十分广泛。<ref name = PMH/> 安非他酮以片剂使用，并且在大部分国家仅可凭处方使用。<ref name = PMH>{{cite web|title=Bupropion (By mouth)|work=PubMed Health|publisher=[[National_Institute_of_Health|National Institute of Health]]|location=[[Bethesda,_Maryland|Bethesda]], USA|date=1 June 2014|accessdate=18 July 2014|url=http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0009361/?report=details|archive-date=2013-11-09|archive-url=https://web.archive.org/web/20131109160652/http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0009361/?report=details|dead-url=no}}</ref> 在台灣有經[[衛生福利部食品藥物管理署|衛生福利部食品藥物管理署]]核准由瑞安大藥廠推出的醫師處方學名藥必博寧（Buporin）。<ref>{{Cite web|title=衛署藥製字第054977號|url=https://info.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=01054977|access-date=2022-02-20|work=info.fda.gov.tw|archive-date=2022-02-20|archive-url=https://web.archive.org/web/20220220054135/https://info.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=01054977}}</ref>化学上，安非他酮属于[[氨基酮|氨基酮]]类化合物。無法使用於有過癲癇歷史的病人身上，否則會增加癲癇機率的風險。

此藥由Burroughs Wellcome藥廠（[[葛蘭素史克|葛蘭素史克]]（GSK）前身）的有機化學暨藥學家[[納里曼·梅達|納里曼·梅達]]（Nariman Mehta）於1969年所發明，並於1974年取得美國專利3819706號<ref>{{US patent|3819706}}</ref>。

== 藥理作用 ==
安非他酮是[[正腎上腺素|正腎上腺素]]及[[多巴胺|多巴胺]]的神經元回收選擇性抑制劑，對於[[血清素|血清素]] 回收的影響相當微弱，也不會抑制[[單胺氧化酶|單胺氧化酶]]。目前還不知道安非他酮藉由何 種機轉來增進患者的[[戒煙|戒煙]]能力。以及雖然其作用機轉與其他[[抗抑郁药|抗抑郁药]]一樣還不明確。 但一般認為，這種作用是由正腎上腺素激性或多巴胺激性機轉所媒介。

== 代謝 ==
安非他酮在人體內進行廣泛代謝。至今已在血漿中鑑定出三種具有藥理活性的代謝物：hydroxybupropion 及其胺基乙醇異構物(amino-alcohol isomers)threohydrobupropion、及 erythrohydrobupropion。

這些代謝物在臨床上可能相當重要，因為它們的血漿濃度和 bupropion 一樣高，甚至更高。活性代謝物進一步代謝成不具活性的代謝物之後，由尿液排出體外。

bupropion 主要被 CYP2B6 代謝成主要的活性代謝物hydroxybupropion；然而，細胞色素 P450s 與 threohydrobupropion 的形成無關

== 副作用 ==

===免疫系統異常===

常 見： 過敏反應如蕁麻疹

極罕見： 更嚴重的過敏反應包括血管性水腫、呼吸困難/支氣管痙攣及過敏性休 克。也有關節痛、肌痛及發燒伴隨皮疹及其他暗示遲發性過敏症狀

===代謝及營養方面異常===

常 見：厭食

不常見：體重減輕 

極罕見：血糖紊亂

===精神方面異常===

極常見：失眠 

常 見：不安、焦慮 

不常見：抑鬱、精神紊亂 

極罕見：侵略性、敵意、易怒、激動、幻覺、異常夢境、人格解體、妄想、偏執 觀念

===神經系統異常===

極常見：頭痛 

常 見：震顫、頭暈、味覺異常 

不常見：注意力障礙 

罕 見：癲癇

極罕見：肌張力不全、運動失調、[[帕金森氏症|帕金森氏症]]、不協調、記憶障礙、皮膚感覺異常、暈厥

===眼睛方面異常===

常 見：視覺障礙 

===心臟方面異常===

不常見：心搏過速 

極罕見：心悸

===血管異常===

常 見：血壓升高(有時嚴重)、潮紅 

極罕見：血管擴張、姿勢性低血壓

===胃腸消化系統異常===

極常見：口乾、胃腸障礙，包括噁心及嘔吐 

常 見：腹痛、便秘

===肝膽系統異常===

極罕見：膽酵素上升、黃膽、肝炎 

===皮膚及皮下組織異常===

常 見：皮疹、搔癢、出汗 

極罕見：多形性紅斑、[[史蒂芬斯－強森症候群|史蒂芬強森症候群]](Stevens Johnson syndrome)

===骨骼肌及結締組織方面異常===

極罕見：痙攣 

===腎臟及泌尿系統異常===

極罕見：頻尿及/或尿液滯留

===全身性的障礙===

常 見：發燒、胸痛、無力

== 過量 ==
服藥過量所導致的症狀包括嗜睡、喪失意識及 [[心电图|ECG]] 變化如傳導紊亂(包括 QRS 延長)或心率不整；曾有致命的案例被通報。

治療過量時，應監控 ECG 及生命徵象。確保呼吸道暢通，以及充分的氧氣供給與換氣。建議使用[[活性炭|活性炭]]。安非他酮沒有已知的特定解毒劑。

== 引用 ==
{{reflist}}

{{抗抑郁药}}
{{ADHD_pharmacotherapies}}
[[Category:抗抑郁药物|Category:抗抑郁药物]]
[[Category:戒烟|Category:戒烟]]
[[Category:去甲肾上腺素-多巴胺重摄取抑制剂|Category:去甲肾上腺素-多巴胺重摄取抑制剂]]
[[Category:叔丁基化合物|Category:叔丁基化合物]]
[[Category:氯苯|Category:氯苯]]
[[Category:降食欲剂|Category:降食欲剂]]
[[Category:春药|Category:春药]]
[[Category:卡西酮|Category:卡西酮]]
[[Category:烟碱型拮抗剂|Category:烟碱型拮抗剂]]